About Us


Howard Solomon

Howard Solomon is a Partner at Hildred Capital Partners. Mr. Solomon is an attorney who began his career working for several law firms in New York City. One of his clients was Forest Laboratories, a pharmaceutical manufacturer and marketer. Ultimately, he became President and Chief Executive Officer of the Company in 1977 and he was elected Chairman and Chief Executive Officer in December 1998. He retired as CEO and President in September 2013 and served as Chairman of the Board, until the company was acquired by Actavis for approximately $28 billion in July 2014.

When Mr. Solomon became CEO of Forest, its pharmaceutical business in the United States consisted of a small and unprofitable vitamin business. Mr. Solomon led the transformation of Forest into an innovative and fully integrated multi-billion-dollar pharmaceutical company. In addition to building value for shareholders, Mr. Solomon was also instrumental in building an industry-leading portfolio of groundbreaking therapies and next generation pharmaceutical products, including blockbuster products, such as Celexa, Lexapro, Benicar and Namenda.

Mr. Solomon is very active in supporting the performing arts, serving as a member of the Executive Committee of the Board of Directors of the Metropolitan Opera and Chairman of the Finance Committee. He is a member of the Board of the New York City Ballet, where he served as Chairman of the Board and Chief Executive officer from 1996 to 2002 and is currently a member of the Executive Committee. In addition, he is a Member Emeritus of the Board of Directors of Lincoln Center for the Performing Arts.

Mr. Solomon also is a trustee of the New York Presbyterian Hospital and a past member of the Board of Cold Spring Harbor Laboratories.

Mr. Solomon attended City College of New York, where he graduated cum laude. He also holds a J.D. from Yale Law School, where he was an editor of the Yale Law Journal.

David F. Solomon


David F. Solomon is a Partner at Hildred Capital Partners. In association with Hildred’s investments, Mr. Solomon currently serves as Chairman of the Board for Crown Laboratories, a specialty pharmaceutical company focused in dermatology. He serves on the Board of Quantum-Si, an innovative life sciences company; he is an Executive Partner at Tyree & D’Angelo, an investment firm focused on acquiring and consolidating individual operating healthcare-related businesses and he is a member of the Shareholder’s Council for Columbia Care, the leading medical marijuana business in the U.S. Prior to Hildred, Mr. Solomon served on the Board of Directors for Moksha8, a Latin American pharmaceutical company with commercial operations in Mexico and Brazil and on the Board of Directors of Trevena, a public clinical stage biotech company, working in the area of G protein coupled receptor targeted medicines.

Prior to launching Hildred Capital Partners, Mr. Solomon spent fourteen years at Forest Laboratories, ultimately as Senior Vice President, Corporate Development & Strategic Planning. In that capacity, Mr. Solomon was responsible for Forest’s Business Development activities, including all M&A, licensing and product acquisitions. He also had responsibility for Forest’s Alliance Management group, which managed Forest’s many collaborations, and its Strategic Planning function, which focused on the review and evaluation of novel business opportunities, as well as life-cycle planning for Forest’s portfolio. In addition, Mr. Solomon managed Forest’s business outside the United States, including its European, Canadian and Latin American operations. He was also responsible for all of the company’s Operations, including Manufacturing and Distribution, as well as its Informatics, Compliance and Quality Affairs functions. Mr. Solomon departed Forest, after the company was acquired by Actavis for approximately $28 billion in July 2014.

Prior to joining Forest, Mr. Solomon practiced entertainment law at Paul Weiss Rifkind Wharton & Garrison in New York. Following that, he worked as Director of Creative Affairs at Paramount Pictures in Los Angeles, overseeing development and production of feature films for the studio and as an independent producer with Davis Entertainment, based at 20th Century Fox. Mr. Solomon has also produced the Peabody Award winning documentary film Rebirth, about a group of people whose lives were dramatically impacted by September 11th, which premiered at the Sundance Film Festival in January 2011.
Mr. Solomon serves on the Board of Directors of Lincoln Center Theater and the Municipal Art Society and on the Executive Board of the Yale Dramat Alumni Association. Mr. Solomon has also served as a member of the Yale University Council Committee on Theater at Yale.

Mr. Solomon graduated summa cum laude with a B.S. in Biology from Yale College, where he was elected to Phi Beta Kappa and received the Jonathan Edwards Fellows Prize for Academic Achievement and the Henry E. Ellsworth Prize for the most significant senior thesis in the Natural Sciences. He received his J.D. from Yale Law School, where he was a Coker Fellow and a Senior Editor of the Yale Law Journal.

Jeff Bedard

Jeff Bedard is the President/CEO of Crown Laboratories, Inc. Before founding Crown Laboratories, Inc. in 2000, Mr. Bedard held positions in sales and market development with Stiefel Laboratories, Inc. and Herald Pharmacal, Inc. Mr. Bedard owned a consulting firm, providing marketing and business development management advice for small to medium pharmaceutical companies.

Mr. Bedard has been a Director of Crown Laboratories, Inc. since 2000 and served previously as Chairman of the Board and President. Mr. Bedard currently serves on the Boards of Northeast Tennessee State Community College Foundation, ETSU Foundation and Mountain States Foundation. He recently was inducted in the Science Hill Sports Hall of Fame.

Mr. Bedard graduated with honors from University of Iowa with a degree in Chemistry.

Andrew Goldman

Andrew Goldman is a Managing Director and Chief Investment Officer with Hildred Capital Partners, where he is responsible for overseeing the Firm’s capital allocation and day-to-day investing activities. In connection with Hildred’s investments, Mr. Goldman currently serves on the Board of Directors for Crown Laboratories, a specialty pharmaceutical company focused in dermatology, and holds a Board Observer seat at Kareo, a leading provider of an integrated software platform for independent physician practices. Prior to joining Hildred, Mr. Goldman was a founding partner in Priam Capital Associates, a series of private equity partnerships, which focused on investments in financial services and banking. Prior to joining Priam, he was a founding partner in De Cordova Goldman Holdings, an opportunistic investor, with investments in natural resources and energy, media and telecommunications and financial services. Mr. Goldman was a strategic advisor to Saxon Strategic Funds, a hedge fund focused on active trading strategies, as well.

Prior to founding De Cordova Goldman Holdings, Mr. Goldman served as a senior advisor to Senator Joseph R. Biden III, until his inauguration as Vice President of the United States in early 2009. Andrew received his B.A. from the University of Delaware and his MBA from The Wharton School at the University of Pennsylvania.

Jack Songster

Chief Operations Officer

Jack Songster was named COO for Crown Laboratories, Inc. in October, 2014 and has been a Board Member of Crown Laboratories, Inc. since 2014. He joined Crown Laboratories in February 2012, assuming responsibility for all operations activities and served as the Vice President of Manufacturing and Site GM at Crown Laboratories’ facility in Johnson City, TN.

Previously, Mr. Songster was Senior Vice President of Manufacturing for Pfizer, Inc. and King Pharmaceuticals, where he held multi-site technical operations responsibility for two solid-dosage and semi-solids plants, a sterile manufacturing site and a chromatographic purification location. Mr. Songster’s wealth of manufacturing and logistics experience in the highly regulated medical device and pharmaceutical industry, totals more than 25 years.

Stephen Hallenbeck

Stephen Hallenbeck is a Principal and the Director of Private Equity with Hildred Capital Partners, where he is responsible for sourcing, executing and managing investment opportunities within the private investments portfolio. In connection with Hildred’s investments, Mr. Hallenbeck currently serves on the Board of Directors for Crown Laboratories, a specialty pharmaceutical company, focused in dermatology, and SportsMed Physical Therapy, a leading provider of high-quality physical therapy, chiropractic, acupuncture, and occupational therapy rehabilitation services.

Prior to joining Hildred, Mr. Hallenbeck was at Deutsche Bank, where he most recently worked in the Financial Sponsors Group. In this role, Mr. Hallenbeck identified and evaluated leveraged acquisitions and capital markets financings for both prospective and current portfolio companies of private equity firms. Prior to this, Mr. Hallenbeck spent time as a member of Deutsche Bank’s Healthcare Investment Banking team, focusing on M&A, debt and equity transactions for both private and public companies, within the sector. Mr. Hallenbeck received a B.A. in Economics, with honors, from Vanderbilt University.

Dan Turner

Dan Turner has 30 years of experience as an entrepreneur, operating manager and investor. He founded Montreux Equity Partners and has been a General Partner and Managing Member with Montreux since 1993.

Mr. Turner has invested in companies across consumer, healthcare services, pharmaceuticals and technology sectors. Some of his previous investments include Paymap (acquired by First Data Corp), Peapod (IPO; acquired by Royal Ahold), and Great Lakes Health Plan (acquired by United Healthcare). Mr. Turner is a member of the board of directors of Avantis Medical, GC Aesthetics, Moksha8, Pure Life Renal, KNOW Foods, and Crown Laboratories, Inc. He is a member of the Advisory Board of the Lester Center, located at the Haas School of Business, University of California, Berkeley.

Mr. Turner previously served as Montreux’s representative to the board of directors of Glaukos (NYSE: GKOS), Tobira Therapeutics, Epirus Biopharmaceuticals (NASDAQ: EPRS), Renal CarePartners (sold to Ambulatory Services of America in 2011), Cerexa (sold to Forest Laboratories in 2007), NovaCardia (sold to Merck in 2007), and Peninsula Pharmaceuticals (sold to Johnson & Johnson in 2005).

Mr. Turner started his career with Price Waterhouse in the high technology group. He later became the founding Chief Financial Officer of Oclassen Pharmaceuticals, a specialty pharmaceutical company, focused in dermatology, which merged with Watson Pharmaceuticals (NYSE: WPI) in 1997. Prior to founding Montreux Equity Partners, Mr. Turner was a Principal in the Turnaround Group for Berkeley International.

He holds a B.S. from California State University, Sacramento and attended the M.B.A. program at the Haas School of Business at the University of California, Berkeley, where he has established the Turner Fellowship. Mr. Turner is a Certified Public Accountant

Alyson Hogg, MBE

Chief Creative Officer

Alyson Hogg is the Founder and Creator of Vita Liberata

Ms. Hogg enjoyed a multi-faceted professional career, which spanned broadcasting, academia, hospitality and politics. She was Communications Director of the Women’s Coalition in Northern Ireland during the 1998 Peace Process, before creating Vita Liberata in 2003. Ms. Hogg has been the inspiration behind the Vita Liberata brand’s phenomenal success.  She joined Crown Laboratories in 2017 and has been a director since 2018.

Ms. Hogg completed her undergraduate studies in Philosophy and was researching her PhD in Philosophy of Psychology, when she decided to focus on business, instead. She holds the position of Distinguished Graduate at the University of Ulster and received the Queen’s Award for Industry in 2014 and 2015. She was awarded the MBE (Member of the Order of the British Empire) in the Queen’s Honours List in 2017.

Joe Proctor

President, Bellus Medical

Joe Proctor is President of Bellus Aesthetics and an award-winning inventor in aesthetics. He launched Bellus Medical in 2012 to help leading physician-directed practices around the world grow their businesses. The aesthetic division of Crown Laboratories since 2018, Bellus specializes in non-invasive innovations that act as “gateway” products to draw new patients to its partners.

Mr. Proctor began his career in aesthetics more than 15 years ago through progressive sales development and training. As a strong influencer in the industry, he leads by example by offering products of the highest quality and safety standards, and by providing best-in-class customer service and education. He is the winner of the Non-Physician Technology Innovator of the Year from The Aesthetic Show with Bellus as the winner of multiple Aesthetic Everything Awards and the SkinPen® microneedling device as the winner of the United Kingdom-based Barry Knapp Award for Product Innovation of the Year.

Adair Newhall

Adair Newhall is a Principal at Greenspring Associates and is responsible for sourcing and due diligence efforts on fund, direct and secondary opportunities. Mr. Newhall currently serves on the Bright Health and Crown Labs Boards & as an Observer on the Paladina Health Board. Adair previously served as a Principal at Domain Associates, a leading healthcare focused venture capital firm and Greenspring Associates fund manager. At Domain Associates, he held board observer positions with several portfolio companies including Applied Proteomics, Astute Medical, BioNano Genomics, CoLucid Pharmaceuticals and Xagenic. He was previously involved as a board observer with Otonomy (NASDAQ: OTIC), which completed a successful initial public offering in August 2014.

Prior to joining Domain Associates in August 2009, Mr. Newhall worked in the Business Development group at Esprit Pharma where he assisted with multiple product acquisitions and the subsequent sale of the company to Allergan (NYSE: AGN) for $370 million. Before that, he worked at ESP Pharma, which was acquired by PDL BioPharma (NASDAQ: PDLI) for $514 million. He received his M.B.A from the Darden Graduate School of Business Administration at the University of Virginia and his undergraduate degree from the University of Pennsylvania.

Currently, Mr. Newhall is a Kauffman Fellow and a co-founder of the UVa Venture Summit.